Progressive Supranuclear Palsy (PSP) is a fatal and rapidly progressive neurodegenerative disease. There are subtypes of disease, the most common of which affects about 5 per 100,000 people. PSP is caused by deterioration of nerve cells in the mid-brain controlling the body’s movement and frontal lobe controlling thoughts and comprehension. Symptoms of the disease are based on the areas most affected by nerve cell loss and commonly include gait disturbance and falls, slowed movements and stiffness, abnormal eye movements, and difficulty with swallowing and speech. Impaired cognitive function and executive planning are also prominent features. The clinical course is rapidly progressive and results in progressive loss of both physical and cognitive function until general debilitation occurs.
There is currently no treatment to modify the progression of PSP.